Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39811 Dogwood Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other juris ...

Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2025 Financial Results - Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study interim data readout is expected in Q4 2025 - - Cash on hand of $17.5M provides operational runway through Q1 2026 - ATLANTA, Ga., May 8, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechno ...

Core Insights - Viridien has sold its Sercel Marlin™ Offshore Logistics management solution to Oil and Natural Gas Corporation (ONGC) to improve operational efficiency and safety in ONGC's Western offshore exploration and production (E&P) operations in India [1][2] - The deal includes a five-year contract for dedicated on-premises software and support services, which will enhance ONGC's logistics through real-time vessel tracking and improved operational planning [1][2] - The integration of advanced AI and machine learning algorithms in the Sercel Marlin solution aims to future-proof ONGC's operations and support its carbon neutrality objectives [2][3] Company Overview - Viridien is a technology and digital company focused on Earth data, aiming to resolve complex challenges in natural resources, energy transition, and infrastructure [4] - The company employs approximately 3,400 people globally and is listed on Euronext Paris SA under the ticker VIRI [4]

Combined General Meeting and Board of Directors Meeting of April 30, 2025 Paris, France – April 30, 2025 The Combined General Meeting of Viridien, chaired by Mr. Philippe SALLE was held on April 30, 2025 in Paris. The voting results and video replay of the event will be available on the Company’s website at the following address: https://www.viridiengroup.com/investors/shareholders/general-meetings. The General Meeting approved all resolutions that were submitted to it and notably: The statutory financia ...

Core Insights - The company achieved significant milestones in Q1 2025, including the termination of a vessel capacity agreement and successful bond refinancing, enhancing operational flexibility and cash generation [3][4][5] - Financial results for Q1 2025 showed a revenue increase of 10% to $301 million and a 35% rise in adjusted EBITDA to $143 million, indicating robust business performance [2][5][9] - The company anticipates generating approximately $100 million in net cash flow for the year, assuming moderate fluctuations in the oil market [4][10] Financial Performance - Q1 2025 revenue reached $301 million, a 10% increase from the previous year, driven by growth in Geoscience and Earth Data segments [2][9] - Adjusted EBITDA for Q1 2025 was $143 million, reflecting a 35% increase, supported by revenue growth and cost reductions [2][5][9] - Net cash flow for Q1 2025 was $(20) million, compared to $30 million in the same period last year, impacted by a $42 million interest payment [2][5][12] Segment Performance - Digital, Data, and Energy Transition (DDE) segment revenue increased by 16% to $214 million, with Geoscience growing by 25% and Earth Data by 7% [5][9] - Sensing and Monitoring (SMO) segment revenue was nearly stable at $87 million, with adjusted EBITDA rising by 37% due to cost reductions [5][9] - The company reported a backlog in Geoscience of $329 million, a 45% increase year-over-year, indicating strong future demand [11] Debt and Liquidity - The company successfully refinanced $447 million and €578 million notes, replacing them with $450 million and €475 million senior secured notes due in October 2030 [5][10] - Net debt stood at $974 million, with liquidity at $257 million, reflecting a focus on cash flow generation and deleveraging [5][11] Future Outlook - The company expects continued growth in Geoscience supported by advanced technology and a strong backlog, alongside improved cash EBITDA in Earth Data following the end of vessel commitment penalty fees [10] - The restructuring plan in Sensing & Monitoring is anticipated to yield further savings, contributing positively to overall profitability [10]

Viridien Société anonyme with a share capital of € 7,161,465 Registered office : 27 avenue Carnot, 91300 Massy, France Evry Trade and Company Register No. 969 202 241 AVAILABILITY AND CONSULTATION OF THE PREPARATORY DOCUMENTS FOR THE VIRIDIEN COMBINED GENERAL MEETING OF WEDNESDAY, APRIL 30, 2025 Paris, France – April 9, 2025 The Combined General Meeting of Viridien (the “Company”) will be held on Wednesday, April 30, 2025 at 10.30 a.m. at Cloud Business Center, 10 bis rue du Quatre Septembre, 75002 Paris, ...

Core Insights - Viridien has been awarded a contract by Groupement Hassi Bir Rekaiz to reimage two legacy 3D seismic data sets totaling 2,400 sq km in the Hassi Bir Rekaiz concession in Eastern Algeria [1][2] - The project will last for 13 months and aims to enhance seismic data quality using advanced technology for better reservoir insights and increased drilling success [2][3] - The contract reflects client confidence in Viridien's expertise and technological advancements in the growing Algerian market [3] Company Overview - Viridien is a technology-driven company focused on Earth data, aiming to resolve complex challenges in natural resources, energy transition, and infrastructure [4] - The company employs approximately 3,500 people globally and is listed on Euronext Paris SA under the ticker VIRI [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39811 DOGWOOD THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Identific ...

Financial Performance - Net loss attributable to common stockholders for Q4 2024 was $8.2 million, or $6.29 per share, compared to a net loss of $1.1 million, or $1.43 per share, in Q4 2023[10]. - For the full year 2024, net loss attributable to common stockholders was $12.9 million, or $12.52 per share, compared to a net loss of $5.3 million, or $7.05 per share, in 2023[14]. Expenses - Research and development expenses for Q4 2024 were $2.3 million, a 567% increase from $0.3 million in Q4 2023[8]. - General and administrative expenses for Q4 2024 were $5.2 million, up 575% from $0.8 million in Q4 2023, primarily due to nonrecurring transaction costs[9]. Capital and Funding - The company converted $19.5 million in debt to equity, significantly improving its balance sheet[5]. - A recent capital raise of $4.8 million, combined with existing cash, provides operational runway through Q1 2026[5]. - As of December 31, 2024, Dogwood Therapeutics had cash totaling $14.8 million, sufficient to fund operations through Q1 2026[14]. Assets and Liabilities - Total assets increased to $94.3 million as of December 31, 2024, compared to $4.2 million in 2023[23]. - Total liabilities rose to $30.0 million as of December 31, 2024, compared to $0.4 million in 2023[23]. Clinical Development - Dogwood Therapeutics commenced dosing in its Halneuron® Phase 2b CINP program, with interim data expected in Q4 2025[5].

Paris, France – March 27, 2025 First Quarter 2025 financial results and conference call Viridien will announce its first quarter 2025 financial results on Tuesday, April 29, after market close. The press release and the presentation will be made available on our website www.viridiengroup.com at 5.45 pm (CET).An English language analysts conference call is scheduled the same day at 6.00 pm (CET). Participants should register for the call here to receive a dial-in number and code or participate in the live we ...